The Department of Veterans Affairs, specifically the Regional Procurement Office - East, intends to negotiate a sole-source contract with Natera, Inc. for conducting circulating tumor DNA (ctDNA) analysis as part of the RIVAL research study, which focuses on immunotherapy in veterans with locally advanced non-small cell lung cancer (NSCLC). The contract will support the analysis of ctDNA levels in approximately 40 patients at various VA medical centers, evaluating changes pre- and post-chemotherapy combined with immunotherapy to predict patient outcomes. Natera's Signatera assay is critical for this study due to its proven sensitivity and specificity, ensuring consistent analysis across baseline and follow-up samples. Interested parties must notify the Contracting Officer, Ms. Millicent Covert, at millicent.covert@va.gov by January 31, 2025, to express their interest and capabilities, as this notice is not a solicitation for competitive proposals.